Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,664
Employees1,664
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,664
Employees1,664

INSM Key Statistics

Market cap
31.19B
Market cap31.19B
Price-Earnings ratio
-22.56
Price-Earnings ratio-22.56
Dividend yield
Dividend yield
Average volume
1.98M
Average volume1.98M
High today
$145.55
High today$145.55
Low today
$141.21
Low today$141.21
Open price
$144.25
Open price$144.25
Volume
2.05M
Volume2.05M
52 Week high
$212.75
52 Week high$212.75
52 Week low
$63.81
52 Week low$63.81

Stock Snapshot

As of today, Insmed Incorporated(INSM) shares are valued at $144.68. The company's market cap stands at 31.19B, with a P/E ratio of -22.56.

On 2026-04-18, Insmed Incorporated(INSM) stock moved within a range of $141.21 to $145.55. With shares now at $144.68, the stock is trading +2.5% above its intraday low and -0.6% below the session's peak.

Trading volume for Insmed Incorporated(INSM) stock has reached 2.05M, versus its average volume of 1.98M.

The stock's 52-week range extends from a low of $63.81 to a high of $212.75.

The stock's 52-week range extends from a low of $63.81 to a high of $212.75.

INSM News

Simply Wall St 1d
Insmed Is Down 10.5% After Halting Brensocatib in HS Trial Miss - What's Changed

Insmed Incorporated recently reported that its Phase 2b CEDAR trial of brensocatib in adults with moderate to severe hidradenitis suppurativa failed to meet pri...

Insmed Is Down 10.5% After Halting Brensocatib in HS Trial Miss - What's Changed
TipRanks 2d
Insmed price target raised to $230 from $227 at Guggenheim

Guggenheim raised the firm’s price target on Insmed (INSM) to $230 from $227 and keeps a Buy rating on the shares. The firm adjusted estimates as part of a Q1 e...

24/7 Wall St. 5d
Stanley Druckenmiller Made 1 Huge Bet That Still Looks Attractive Today and Cut 2 Top Positions

Stanley Druckenmiller Made 1 Huge Bet That Still Looks Attractive Today and Cut 2 Top Positions By Thomas Richmond Published Apr 13, 2:36PM EDT Quick Read Sta...

Stanley Druckenmiller Made 1 Huge Bet That Still Looks Attractive Today and Cut 2 Top Positions

Analyst ratings

100%

of 22 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.